Current role
Biotechnology · Healthcare
CEO, Board Member
2023-07-01–present
Alex C. Sapir
Board Member
Fulcrum Therapeutics, Inc. (FULC)Equibles does not estimate personal net worth.
Get an email with a short summary when Fulcrum Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get FULC alertsAbout Alex C. Sapir
Alex C. Sapir is recorded as Board Member at Fulcrum Therapeutics, Inc. (FULC) since July 1, 2023 and CEO at Fulcrum Therapeutics, Inc. (FULC). Fulcrum Therapeutics, Inc. reported in an 8-K filed May 15, 2023 that Alex C. Sapir was appointed president and chief executive officer, effective July 1, 2023. Fulcrum Therapeutics, Inc. reported in an 8-K filed May 15, 2023 that Alex C. Sapir was appointed class II director, effective July 1, 2023. The proxy statement of Fulcrum Therapeutics, Inc. reports total compensation of $3,251,490 for Alex C. Sapir in fiscal 2025, including a base salary of $650,000. Disclosed compensation is on record for 3 fiscal years. Fulcrum Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Fulcrum Therapeutics, Inc. includes Bryan Stuart (CEO, COO and Board Member), Robert J. Gould (CEO), Kate Haviland (Chairman) and 7 others.
“On May 11, 2023, the Board also appointed Alex C. Sapir as Fulcrum's president and chief executive officer, and as a class II director, effective July 1, 2023.”
“On May 11, 2023, the Board also appointed Alex C. Sapir as Fulcrum's president and chief executive officer, and as a class II director, effective July 1, 2023.”
Affiliation history
-
Current
2023-07-01–present
-
Current
Company network
Leadership on record at Fulcrum Therapeutics, Inc.
- Bryan Stuart CEO, COO, Board Member
- Robert J. Gould CEO
- Kate Haviland Chairman
- Mark Levin Chairman
- Alan A. Musso CFO
- Peter Thomson CFO
- Robert E. Gould CFO
- Mel Hayes COO
- Alan Musso Chief Accounting Officer
- Gregory Tourangeau Chief Accounting Officer
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Fulcrum Therapeutics, Inc. (FULC) | President and Chief Executive Officer | $650,000 | $3,251,490 |
| 2024 | Fulcrum Therapeutics, Inc. (FULC) | President and Chief Executive Officer | $650,000 | $1,003,300 |
| 2023 | Fulcrum Therapeutics, Inc. (FULC) | President and Chief Executive Officer | $369,419 | $6,990,596 |